Management of the adverse effects of clozapine

Schizophrenia Bulletin

Volumn 24, Issue 3, 1998, Pages 381-390

  Young, Carl R ^b   Bowers Jr , Malcolm B ^b   Mazure, Carolyn M ^a,b  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Atypical antipsychotics; Clozapine; Side effects

Indexed keywords

AMITRIPTYLINE; ATENOLOL; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; DESMOPRESSIN; DEXAMPHETAMINE; DIHYDROERGOTAMINE; EPHEDRINE; FLUDROCORTISONE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEVODOPA; METHYLPHENIDATE; OXYBUTYNIN; PROPRANOLOL;

AGRANULOCYTOSIS; ARTICLE; CONSTIPATION; DELIRIUM; DOSE CALCULATION; DROWSINESS; DRUG SAFETY; HUMAN; HYPERSALIVATION; NAUSEA; NEUROTOXICITY; OBSESSION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SEIZURE; TACHYCARDIA;

EID: 0031849782     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033333     Document Type: Article

References (92)

1. Alvir, J.M., and Lieberman, J.A. Agranulocytosis: Incidence and risk factors. Journal of Clinical Psychiatry, 55(Suppl. B):137-138, 1994.
2. Alvir, J.M.; Lieberman, J.A.; Safferman, A.Z.; Schwimmer, J.L.; and Schaaf, J.A. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States. New England Journal of Medicine, 329:162-167, 1993.
3. Aronowitz, J.S.; Safferman, A.Z.; and Lieberman, J.A. Management of clozapine induced enuresis. [Letter] American Journal of Psychiatry, 152:472, 1995.
4. Bak, T.H.; Bauer, M.; Schaub, R.T.; Hellweg, R.; and Reischies, F.M. Myoclonus in patients treated with clozapine: A case series. Journal of Clinical Psychiatry, 56:418-422, 1995.
5. Baker, R.W.; Chengappa, K.N.; Baird, J.W.; Steingard, M.D.; Christ, M.A.; and Schooler, N.R. Emergence of obsessive-compulsive symptoms during treatment with clozapine. Journal of Clinical Psychiatry, 53(12):439-442, 1992.
6. Baldessarini, R.J., and Frankenburg, F.R. Clozapine: A novel antipsychotic agent. New England Journal of Medicine, 324:746-754, 1991.
7. Beach, P.S.; Beach, R.E.; and Smith, L.R. Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rational approach to fluid intake. Clinical Pediatrics, 31:566-569, 1992.
8. Berman, I.; Zalma, A.; Durand, C.J.; and Green, A.I. Clozapine-induced myoclonic jerks and drop attacks. [Letter] Journal of Clinical Psychiatry, 53:329-330, 1992.
9. Bernstein, J.G. Psychotropic drug induced weight gain: Mechanism and management. Clinical Neuropharmacology, 11(Suppl. 1):194-206, 1988.
10. Bourgeois, J.A.; Drexler, K.G.; and Hall, M.J. Hypersalivation and clozapine. [Letter] Hospital and Community Psychiatry, 42:1174, 1991.
11. Burke, M., and Sebastian, C.S. Treatment of clozapine sedation. [Letter] American Journal of Psychiatry, 150:127, 1993.
12. Cassidy, S.L., and Thaker, G.K. Addition of fluoxetine to clozapine. American Journal of Psychiatry, 149:1900-1901, 1993.
13. Cates, M.; Lusk, K.; Wells, B.G.; and Guthrie, T.C. Non-leukopenic neutropenia in a patient treated with clozapine. New England Journal of Medicine, 326:840-841, 1992.
14. Centorrino, F.; Baldessarini, R.J.; Kando, J.; Frankenburg, F.R.; Volpicelli, S.A.; Puopolo, P.R.; and Flood, J.G. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry, 151(1):123-125, 1994.
15. Chengappa, K.N.R.; Baker, R.W.; and Harty, I. Seizures and clozapine dosing schedule. [Letter] Journal of Clinical Psychiatry, 55:456, 1994a.
16. Chengappa, K.N.R.; Shelton, M.D., Baker, R.W.; Schooler, N.R.; Baird, J.; and Delaney, J. The prevalence of akathisia in patients receiving stable doses of clozapine. Journal of Clinical Psychiatry, 55:142-145, 1994b.
17. Cleophas, T.J.M., and Kauw, F.H.W. Pressor responses from noncardioselective beta-blockers. Angiology, 39:587-596, 1988.
18. Cohen, S. Sedation. In: Yesavage, J., ed. Clozapine: A Compendium of Selected Readings. Stanford, CA: Sandoz Pharmaceuticals Corporation, 1992. pp. 132-133.
19. Cohen, B.M.; Keck, P.E.; Satlin, A.; and Cole, J.O. Prevalence and severity of akathisia in patients on clozapine. Biological Psychiatry, 29:1215-1219, 1991.
20. Cohen, S.A., and Underwood, M.T. The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry, 55:440-444, 1994.
21. Copp, P.J., Lament, R.; and Tennent, T.G. Amitriptyline in clozapine-induced sialorrhea. [Letter] British Journal of Psychiatry, 159:166, 1991.
22. Druss, B.G., and Mazure, C.M. Transient fever and hematologic abnormalities during clozapine use. Journal of Clinical Psychopharmacology, 13:155-156, 1993.
23. Eggert, A.E.; Crimson, M.L.; Dorson, P.G.; and Taylor, R.L. Clozapine rechallenge after marked liver enzyme elevation. Journal of Clinical Psychopharmacology, 14:425-426, 1994.
24. Fleischhacker, W.W.; Hummer, M.; Kurz, M.; Kurzthaler, I.; Lieberman, J.A.; Pollack, S.; Safferman, A.Z.; and Kane, J.M. Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects. Journal of Clinical Psychiatry, 55(Suppl. B):78-81, 1994a.
25. Fleischhacker, W.W.; Meise, U.; Gunther, V.; and Kurz, M. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatrica Scandinavica, 89:11-15, 1994b.
26. Frankenburg, F.R.; Kando, J.C.; Centorrino, F.; and Gilbert, J.M. Bladder dysfunction associated with clozapine therapy. Journal of Clinical Psychiatry, 57:39-40, 1996.
27. Fritze, J., and Elliger, T. Pirenzepine for clozapine-induced hypersalivation. [Letter] Lancet, 346:1034, 1995.
28. Gaertner, H.J.; Fischer, E.; and Hoss, J. Side effects of clozapine. Psychopharmacology, 99(Suppl.):97-100, 1989.
29. Gerson, S.L. G-CSF and the management of clozapine induced agranulocytosis. Journal of Clinical Psychiatry, 55(Suppl. B):139-142, 1994.
30. Gerson, S.L.; Aree, C.; and Meltzer, H.Y. N-Desmethyl-clozapine: A clozapine metabolite that suppresses haemopoiesis. British Journal of Haematology, 86:555-561, 1994.
31. Gerson, S.L.; Lieberman, J.A.; Friedenberg, W.R.; Lee, D.; and Marx, J.J. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet, 338:262-263, 1991.
32. Ghaemi, S.N.; Zarate, C.A.; Popli, A.P.; Pillay, S.S.; and Cole, J.O. Is there a relationship between clozapine and obsessive-compulsive disorder?: A retrospective chart review. Comprehensive Psychiatry, 36:267-270, 1995.
33. Gouzoulas, E.; Ozdagler, A.; and Kaspar, J. Myoclonic seizures followed by grand mal seizures during clozapine treatment. [Letter] American Journal of Psychiatry, 150:1128, 1993.
34. Grabowski, J. Clonidine treatment of clozapine-induced hypersalivation. Journal of Clinical Psychopharmacology, 12:69-71, 1992.
35. Grohmann, R.; Ruther, E.; Sassim, N.; and Schmidt, L.G. Adverse effects of clozapine. Psychopharmacology, 99:101-104, 1989.
36. Gunther, W.; Baghai, T.; Naber, N.; and Spatz, R. EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients. Pharmacopsychiatry, 26:69-74, 1993.
37. Haller, E., and Binder, R.L. Clozapine and seizures. American Journal of Psychiatry, 147:1069-1071, 1990.
38. Hayes, G., and Gibier, B. Clozapine-induced constipation. [Letter] American Journal of Psychiatry, 152:298, 1995.
39. Hummer, M.; Kurz, M.; Barnas, C.; Saria, A.; and Fleischhacker, W.W. Clozapine-induced transient white blood count disorders. Journal of Clinical Psychiatry, 55:429-432, 1994.
40. Jann, M.W; Grimsley, S.R.; Gray, E.C.; and Chang, W.H. Pharmacodynamics and pharmacokinetics of clozapine. Clinical Pharmacokinetics, 24:161-176, 1993.
41. Jerling, M.; Lindstrom, L.; Bondesson, U.; and Bertilsson, L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring, 16(4):368-374, 1994.
42. Kane, J.; Honigfeld, G.; Singer, J.; and Meltzer, H. Clozaril Collaborative Group: Clozapine for treatment-resistant schizophrenia: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
43. Kellner, M.; Wiedemann, K.; Krieg, J.C.; and Berg, P.A. Toxic hepatitis by clozapine treatment. [Letter] American Journal of Psychiatry, 150:985-986, 1993.
44. Konicki, P.E.; Borovicka, M.; and Fuller, M. "Incidence and Treatment of Clozapine-Associated Urinary Incontinence." Presented at the 34th conference of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1995.
45. Kronig, M.H.; Munne, R.A.; Szymanski, S.; and Safferman, A.Z. Plasma clozapine levels and therapeutic response for treatment-refractory schizophrenic patients. American Journal of Psychiatry, 152:179-182, 1995.
46. Krupp, P., and Barnes, P. Leponex-associated granulocytopenia: A review of the situation. Psychopharmacology, 99:118-121, 1989.
47. Lamberti, J.S.; Bellnier, T.; and Schwarzkopf, S.B. Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry, 149:689-690, 1992.
48. Leadbetter, R.; Shutty, M.; Pavalonis, D.; Vieweg, V. Higgins P.; and Downs, M. Clozapine weight gain and clinical relevance. American Journal of Psychiatry, 149:68-72, 1992.
49. Lennard-Jones, J.E. Clinical management of constipation. Pharmacology, 47:216-223, 1993.
50. Levin, H.; Chengappa, K.N.R.; Kambhamati, R.K.; Mahdavi, N.; and Ganguli, R. Should treatment refractory akathisia be an indication for the use of clozapine in schizophrenic patients? Journal of Clinical Psychiatry, 53:248-251, 1992.
51. Levkovitch, Y.; Kronnenberg, Y.; and Gaoni, B. Can clozapine trigger OCD? [Letter] Journal of American Academy of Child and Adolescent Psychiatry, 34(3):263, 1995.
52. Lieberman, J.A.; Kane, J.M.; and Johns, C.A. Clozapine: Guidelines for clinical management. Journal of Clinical Psychiatry, 50:329-338, 1989.
53. Lieberman, J.A., and Safferman, A.Z. Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatric Quarterly, 63:51-70, 1992.
54. Lieberman, J.A.; Yunis, J.; Egea, E.; Canoso, R.T.; and Kane, J.M. HLA-B38, DR4, Dqw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry, 47:945-948, 1990.
55. Marinkovic, D.; Timtijevic, I.; Babinski, T.; and Totic S. The side effects of clozapine: A four year follow-up study. Progressive Neuropsychopharmacology, 18:537-544, 1994.
56. Markowitz, J.S.; Wells, B.G.; and Carson, W.H. Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy, 29:603-609, 1995.
57. Mazure, C.M.; Nelson, J.C.; Jatlow, P.I. Kincare, P.; and Bowers M.B. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. Journal of Clinical Psychiatry, 51:330-333, 1990.
58. Mazure, C.M.; Sernyak, M.; and Conrad, C.D. Refinements in the treatment of acute psychosis. Resident and Staff Physician, 38:93-100, 1992.
59. Meltzer, H.Y. Treatment of schizophrenia. In: Schatzberg, A.F., and Nemeroff, C.B., eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press, 1995. pp. 631-639.
60. Meltzer, H.Y., and Ranjan, R. Valproic acid treatment of clozapine-induced myoclonus. [Letter] American Journal of Psychiatry, 151:1246-1247, 1994.
61. Nitenson, N.C.; Kando, J.C.; Frankenburg, F.R.; and Zanarini, M.C. Fever associated with clozapine administration. [Letter] American Journal of Psychiatry, 152(7):1102, 1995.
62. Pacia, S.V., and Devinsky, O. Clozapine-related seizures: Experience with 5,629 patients. Neurology, 44:2247-2249, 1994.
63. Patel, B., and Tandon, R. Development of obsessive-compulsive symptoms during clozapine treatment. [Letter] American Journal of Psychiatry, 150(5):836, 1993.
64. Patil, V.J. Development of transient obsessive-compulsive symptoms during treatment with clozapine. [Letter] American Journal of Psychiatry, 149(2):272, 1992.
65. Patterson, T. Sedation. In: Yesavage, J., ed. Clozapine: A Compendium of Selected Readings. Stanford, CA: Sandoz Pharmaceutical Corporation, 1992. pp. 136-138.
66. Pearlman, C. Clozapine, nocturnal sialorrhea, and choking. [Letter] Journal of Clinical Psychopharmacology, 14:283, 1994.
67. Perry, P.J.; Miller, D.D.; Arndt, S.V.; and Cadoret, R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. American Journal of Psychiatry, 148(2):231-235, 1991.
68. 51Cr release assay of clozapine-induced cytotoxicity: Evidence for immunogenic mechanism. Journal of Clinical Psychiatry, 55(Suppl. B):143-148, 1994.
69. Potkin, S.G.; Bera, R.; Gulasekaram, B.; Costa, J.; Hayes, S.; Jin, Y.; Richmond, G.; Carreon, D.; Sitanggan, K.; Gerber, B.; Telford, J.; Pion, L.; Pion, H.; Park, L.; Chang, Y.-J.; Oldroyd, J.; and Cooper, T.B. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry, 55(Suppl.B):133-136, 1994.
70. Ratey, J.J.; Leveroni, C.; Kilmer, D.; Gutheil, C.; and Swartz, B. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. Journal of Clinical Psychiatry, 54:219-223, 1993.
71. Rechlin, T.; Claus, D.; and Weis, M. Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine. Biological Psychiatry, 35:888-892, 1994.
72. Safferman, A.Z.; Kane, J.M.; Aronowitz, J.S.; Gordon, M.F.; Pollack, S.; and Lieberman, J.A. The use of clozapine in neurologic disorders. Journal of Clinical Psychiatry, 55(Suppl. B):98-101, 1994.
73. Safferman, A.Z.; Lieberman, J.A.; Alvir, J.M.J.; and Howard, A. Rechallenge in clozapine induced agranulocytosis. [Letter] Lancet, 339:1296-1297, 1992a.
74. Safferman, A.Z.; Lieberman, J.A.; Kane, J.M.; Szymanski, S.; and Kinon, B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 17(2):247-261, 1991.
75. Safferman, A.Z.; Lieberman, J.A.; Pollack, S.; and Kane, J.M. Clozapine and akathisia. [Letter] Biological Psychiatry, 31:753-754, 1992b.
76. Safferman, A.Z.; Lieberman, J.A.; Pollack, S.; and Kane, J.M. Akathisia and clozapine treatment. [Letter] Journal of Clinical Psychopharmacology, 13:286-287, 1993.
77. Sandoz Pharmaceuticals Company. Clozaril (Clozapine) Treatment Trends. Vol. 4. 1995. pp. 1-4.
78. Sandoz Pharmaceuticals Company. Clozaril (clozapine) product information. In: Arky, R., ed. Physicians Desk Reference. 49th ed. Montvale, NJ: Medical Economics Company, 1996. pp. 2149-2153.
79. Schatz, I.J. Orthostatic hypotension. Archives of Internal Medicine, 144:1037-1041, 1984.
80. Schuster, P.; Gabriel, E.; Kufferle, B.; Strobl, G.; and Karobuth, M. Reversal by physostigmine of clozapine-induced delirium. Clinical Toxicology, 10:437-441, 1977.
81. Simpson, G.M., and Cooper, T.A. Clozapine levels and convulsions. American Journal of Psychiatry, 135:99-100, 1978.
82. Stanilla, J.K.; Nair, C.; de Leon, J.; Josiassen, R.; and Simpson, G.M. "Lack of Akathisia During Clozapine Treatment." Presented at the 34th conference of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1995.
83. Steingard, S. Use of desmopressin to treat clozapine-induced nocturnal enuresis. [Letter] Journal of Clinical Psychiatry, 55:325-316, 1994.
84. Stricker, B.H.C., and Tielens, J.A.E. Eosinophilia with clozapine. Lancet, 338:1520-1521, 1991.
85. Szymanski, S.; Jody, D.; Leipzig, R.; Masiar, S.; and Lieberman, J. Anticholinergic delirium caused by retreatment with clozapine. [Letter] American Journal of Psychiatry, 148:1752, 1992.
86. Testani, M. Clozapine-induced orthostatic hypotension treated with fludrocortisone. Journal of Clinical Psychiatry, 55:497-498, 1994.
87. Thulesius, O., and Berlin, E. Dihydroergotamine therapy in orthostatic hypotension due to psychotropic drugs. International Journal of Clinical Therapeutics and Toxicology, 24:465-467, 1986.
88. Umbricht, D.S.G.; Pollack, S.; and Kane, J.M. Clozapine and weight gain. Journal of Clinical Psychiatry 55:157-160, 1994.
89. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 350:610-614, 1991.
90. Wadworth, A.N.; Murdoch, D.; and Brogden, R.N. Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs, 42:468-510, 1991.
91. Wirshing, W.C.; Phelan, C.K.; Van Putten, T.; Marder, S.R.; and Engel, J. Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia. [Letter] Journal of Clinical Psychopharmacology 10:371-373, 1990.
92. Zarate, C.A.; Tohen, M.; and Baldessarini, R.J. Clozapine in severe mood disorders. Journal of Clinical Psychiatry 56:411-417, 1995.